David D. Halbert - 11 Aug 2025 Form 4 Insider Report for Caris Life Sciences, Inc.

Reporting relationship: Founder, Chairman, and Chief Executive Officer, Director, 10%+ Owner
Issuer ticker: CAI on Nasdaq
Reported as of: 11 Aug 2025
Net transaction value: -$4,223,191
SEC form: 4
Accepted by SEC: 13 Aug 2025, 20:05:16 UTC
Prior SEC filing: 17 Jun 2025
Next SEC filing: 10 Mar 2026
Source filing: View source filing
Reporting owner signature: /s/ J. Russel Denton, Attorney-in-Fact for David D Halbert

Key filing fact

David D. Halbert filed Form 4 for Caris Life Sciences, Inc. on 13 Aug 2025.

Key facts

This page summarizes David D. Halbert's Form 4 filing for Caris Life Sciences, Inc..
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 13 Aug 2025, 20:05.

Change

Previous filing in this sequence was filed on 17 Jun 2025.
Current net transaction value: -$4,223,191.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001034380 Primary reporting owner

HALBERT DAVID D

Relationship: Founder, Chairman, and Chief Executive Officer, Director, 10%+ Owner
Address: C/O CARIS LIFE SCIENCES, INC., 750 W. JOHN CARPENTER FREEWAY, SUITE 800, IRVING
Signature: /s/ J. Russel Denton, Attorney-in-Fact for David D Halbert
Signature date: 13 Aug 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

CAI transaction

Common Stock

Tax liability

Transaction value: $4,223,191
Shares: -141,956
Change %: -5.8%
Price: $29.75
Shares after: 2,295,133
Date: 11 Aug 2025
Ownership: Direct

CAI holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 121,025,002
Date: 11 Aug 2025
Ownership: See Footnotes
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

The Common Stock reported herein includes (i) 101,261,532 shares of Common Stock held of record by Caris Halbert, L.P, (ii) 8,528,805 shares of Common Stock held of record by ADAPT I Ltd., (iii) 8,414,427 shares of Common Stock held of record by Carisome I, L.P., (iv) 645,149 shares of Common Stock held of record by Caris Investment II Ltd, and (v) 2,175,089 shares of Common Stock held of record by Caris Investment III Ltd. Caris Investment Management, LLC is the general partner of each of Caris Halbert, L.P., Caris Investment II Ltd., and Caris Investment III Ltd. Two family trusts are separately the general partner of ADAPT I Ltd. and the managing general partner of Carisome I, L.P., respectively.

Footnote F2

David D. Halbert is the managing member of Caris Investment Management, LLC and the trustee of each of the two family trusts, and in such capacities, has voting and investment power with respect to the shares held of record by each of the foregoing entities. Mr. Halbert disclaims beneficial ownership except to the extent of his pecuniary interest therein.

SEC remarks

Founder, Chairman, and Chief Executive Officer